Compare AU
Compare VEQ vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard FTSE Europe Shares ETF (VEQ) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VEQ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 101 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,661.48 | $1,882.65 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
VEQ | DRUG | |
|---|---|---|
Strategy | VEQ.AX was created on 2015-12-09 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard FTSE Europe Shares ETF seeks to track the return of the FTSE Developed Europe All Cap Index (with net dividends reinvested) in Australian dollars, before taking into account fees, expenses and tax. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Nestle SA (2.78 %) ASML Holding NV (2.40 %) Novo Nordisk A/S Class B (2.14 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Financials (17.53 %) Industrials (15.69 %) Health Care (14.17 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United Kingdom of Great Britain and Northern Ireland (22.70 %) Switzerland (15.45 %) France (14.02 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.35 % | 0.57 % |
Key Summary
VEQ | DRUG | |
|---|---|---|
Issuer | Vanguard | BetaShares |
Tracking index | FTSE Developed Europe All Cap Index - AUD - AU Dollar | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.57 % |
Price | $74.45 | $8.15 |
Size | N/A | $182.401 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 2.56 % | 1.90 % |
Market | ASX | ASX |
First listed date | 11/12/2015 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VEQ | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 101 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,661.48 | $1,882.65 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
VEQ | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VEQ | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |